Product Details

• Catalog Number: T0843
• Unit Size: 1×10^6 cells / 1.0 ml
• Species: Human (Homo sapiens)
• Tissue: Peripheral blood
• Donor Information: CD34⁺-enriched mononuclear cells from a donor with aspirin-exacerbated respiratory disease
• Cell Type: Immortalized Mast Cells
• Morphology & Growth Properties: Suspension; round morphology (may attach in non-upright culture vessels)
• Biosafety Level: BSL-2
• Storage Conditions: Vapor phase of liquid nitrogen or below -130°C
• Shipping Conditions: Shipped on dry ice
• Format: Cryopreserved frozen cells
• Incubation Conditions: 37°C, 5% CO₂
• Immortalization Method: Spontaneous immortalization

Overview

LUVA cells are an immortalized mast cell line established from CD34⁺ progenitors cultured with stem cell factor (SCF), interleukin-6, and transient interleukin-3 exposure. These cells contain metachromatic cytoplasmic granules immunoreactive for tryptase, cathepsin G, and carboxypeptidase A3, and they express transcripts for FcεRI, c-kit, chymase, histidine decarboxylase, CPA3, and the type 1 receptor for cysteinyl leukotrienes.

LUVA can be propagated without SCF supplementation while maintaining functional c-kit and FcεRI signaling. Although FcεRI positivity is limited (~5% of cells), LUVA exhibits modest histamine release compared to LAD2, providing a reproducible system for mast cell biology and drug research applications.

Key Features and Benefits

• Defined Origin: Derived from CD34⁺ blood mononuclear cells of an aspirin-exacerbated respiratory disease donor.
• Granule Marker Profile: Positive for tryptase, cathepsin G, and carboxypeptidase A3.
• Functional Signaling: Retains c-kit and FcεRI signaling pathways.
• SCF-Independent Growth: Cultured without exogenous stem cell factor.
• Selective and Reliable Model: Limited FcεRI expression with modest histamine release, offering a stable and reproducible system for immunology and drug research.

Culture & Handling Guidelines

Recommended Culture Conditions

• Culture Vessel: SpheroWell™ T75 Flask (G7543) or upright PriCoat™ T25 Flasks (G299)
• Growth Medium: PriGrow X Series Medium (TM0843) supplemented with:
  • 2 mM L-glutamine (G275)
  • 1% Penicillin/Streptomycin Solution (G255)
• Incubation: Maintain at 37°C in a humidified atmosphere with 5% CO₂.
• Seeding Density: 1 × 10⁵ – 3 × 10⁵ cells/ml.
• Doubling Time: 24-48 hours.
• Note: Do not culture or freeze with FBS.

Thawing Protocol

1. Thaw cells quickly in a 37°C water bath (≤ 2 minutes), keeping the vial cap above water.
2. Decontaminate the vial exterior with 70% ethanol before transferring into a biosafety cabinet.
3. Transfer cell suspension into a 15 mL sterile tube with 5 mL pre-warmed complete medium.
4. Centrifuge at 125×g for 5–7 minutes and discard the supernatant.
5. Resuspend the pellet in fresh complete medium and dispense into a T75 culture flask.

Subculturing Guidelines

• Change the medium every 2–3 days and keep cell density ≤ 1 × 10⁶ cells/mL.
• Split cultures at a 1:2 to 1:20 ratio (1:10 typically reaches confluence in 3–4 days).
• Centrifuge at 125×g for 5 minutes, resuspend in fresh medium, and transfer into new culture vessels.

Cryopreservation Guidelines

• Cryopreservation Medium: Complete medium supplemented with 8% DMSO.
• Freezing Procedure: Freeze gradually at -1°C/min before transfer to liquid nitrogen.

Related Products

• Recombinant Human SCF (E. coli) – Z100815
• Recombinant Human TGF Beta-1 (TGFB1) – Z101555
• Recombinant Human TNF – Z101385

Disclaimer

• This product is for research use only. Not intended for human or animal diagnostic, therapeutic, or clinical applications.
• The user is responsible for verifying the suitability of this product for their specific experimental conditions.
• Handling and usage should comply with all relevant biosafety regulations.
• No warranties, express or implied, are provided regarding the performance of this product outside of the recommended conditions.

References

• Kirshenbaum, Arnold S., et al. “Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-kit+, and expresses aminopeptidase N (CD13).” Blood, The Journal of the American Society of Hematology 94.7 (1999): 2333-2342.
• Kirshenbaum, Arnold S., et al. “Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcεRI or FcγRI.” Leukemia research 27.8 (2003): 677-682.
• Laidlaw, Tanya M., et al. “Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI.” Journal of allergy and clinical immunology 127.3 (2011): 815-822.